-
Mashup Score: 14Melanoma Treatment: The Heart Has Skin in the Game∗ - 1 year(s) ago
Corresponding Author
Source: JACC: CardioOncologyCategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 0
Phase 2 trial achieves some success, and responders had infiltrate of plasmacytoid dendritic cells.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#Stage3 #Melanoma attacked with #Immunotherapy and a virus-like particle👇 https://t.co/psJkq0TLD9 @MDedgeHemOnc @jimkling #BRAF #MEK https://t.co/DHYXBwcSKe
-
-
Mashup Score: 1Efficacy and Safety of Trametinib in Non‐V600 BRAF Mutant Melanoma: A Phase II Study - 2 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Clinical Trial Results Efficacy and Safety of Trametinib in Non‐V600 BRAF Mutant Melanoma: A Phase II Study #Trametinib #BRAF #Melanoma #Fusion #MEK https://t.co/uHjrsLOlFj https://t.co/I21k9yDuWc
-
-
Mashup Score: 1DIPG harbour alterations targetable by MEK inhibitors, with acquired resistance mechanisms overcome by combinatorial inhibition - 3 year(s) ago
The survival of children with DIPG remains dismal, with new treatments desperately needed. In a prospective biopsy-stratified clinical trial, we combined detailed molecular profiling and drug screening in newly-established patient-derived models in vitro and in vivo. We identified in vitro sensitivity to MEK inhibitors in DIPGs harbouring MAPK pathway alterations, however treatment of PDX models…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
DIPG harbour alterations targetable by #MEK inhibitors, with acquired resistance mechanisms overcome by combinatorial inhibition. https://t.co/D6TBiQJjew @ElisaIzquierdo_ @ICR_London https://t.co/L6hrebJl2R
-
-
Mashup Score: 0JNCCN 360 - Non-Melanoma Skin Cancers - Topical MEK Inhibitor Under Study in Cutaneous Squamous Cell Carcinoma - 3 year(s) ago
By: Jocelyn Solis-Moreira, MS Posted: Friday, May 7, 2021 Preclinical research presented at the 2021 Society for Investigative Dermatology Virtual Meeting (Abstract 487) suggests the topical MEK inhibitor NFX-179 is safe and effective in the chemoprevention of cutaneous squamous cell carcinoma. Kenneth Y….
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Topical #MEK inhibitor under study in cutaneous squamous cell carcinoma: https://t.co/kR2lKdFE51 #skcsm #SID2021 #JNCCN360 https://t.co/GZ7duNVzVI
-
-
Mashup Score: 1Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy - 3 year(s) ago
Colorectal cancer is driven by mutations that activate canonical WNT/β-catenin signaling, but inhibiting WNT has significant on-target toxicity, and there are no approved therapies targeting dominant oncogenic drivers. We recently found that activating a β-catenin–independent branch of WNT signaling that inhibits GSK3-dependent protein degradation induces asparaginase sensitivity in…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
March is #CRCAwarenessMonth. BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined #MEK inhibition. @MarcoHHofmann @Boehringer #DrugDevelopment https://t.co/Fopi2XNw1r https://t.co/M5bgl36YPJ
-
-
Mashup Score: 1BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition - 3 year(s) ago
KRAS is the most frequently mutated driver of pancreatic, colorectal, and non–small cell lung cancers. Direct KRAS blockade has proved challenging, and inhibition of a key downstream effector pathway, the RAF–MEK–ERK cascade, has shown limited success because of activation of feedback networks that keep the pathway in check. We hypothesized that inhibiting SOS1, a KRAS activator and important…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined #MEK inhibition. @MarcoHHofmann @norbertkraut1 @Boehringer #DrugDevelopment https://t.co/uAb7JKPKlY https://t.co/AwwYclF1us
-
-
Mashup Score: 2BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition - 4 year(s) ago
KRAS is the most frequently mutated driver of pancreatic, colorectal, and non-small cell lung cancers. Direct KRAS blockade has proven challenging and inhibition of a key downstream effector pathway, the RAF-MEK-ERK cascade, has shown limited success due to activation of feedback networks that keep the pathway in check. We hypothesized that inhibiting SOS1, a KRAS activator and important feedback…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marco H. Hofmann is speaking about his article: A10 BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined #MEK inhibition. @norbertkraut1 @Boehringer #DrugDevelopment #ENASymp https://t.co/zccstxNrne https://t.co/j9cPBDxW3P
-
-
Mashup Score: 1BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition - 4 year(s) ago
KRAS is the most frequently mutated driver of pancreatic, colorectal, and non-small cell lung cancers. Direct KRAS blockade has proven challenging and inhibition of a key downstream effector pathway, the RAF-MEK-ERK cascade, has shown limited success due to activation of feedback networks that keep the pathway in check. We hypothesized that inhibiting SOS1, a KRAS activator and important feedback…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined #MEK inhibition. @MarcoHHofmann @norbertkraut1 #ESMO20 https://t.co/zDD5j95sCp https://t.co/wPJujW62d3
-
-
Mashup Score: 0BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition - 4 year(s) ago
KRAS is the most frequently mutated driver of pancreatic, colorectal, and non-small cell lung cancers. Direct KRAS blockade has proven challenging and inhibition of a key downstream effector pathway, the RAF-MEK-ERK cascade, has shown limited success due to activation of feedback networks that keep the pathway in check. We hypothesized that inhibiting SOS1, a KRAS activator and important feedback…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined #MEK inhibition. @MarcoHHofmann @norbertkraut1 @Boehringer #DrugDevelopment https://t.co/oSAiKGFB7v https://t.co/nPmttMLA5n
-
Read #JACCardioOnc's editorial regrading #MEK-inhibitor based therapies and #cardiotoxicity. Great insights, but questions remain 👉 https://t.co/11Q6RtnEgT #CardioOnc #MELsm #Melanoma #CardioTwitter @SALLOUMFN